Gilead Sciences, Inc.
GILD- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000882095
In the last 90 days, Gilead Sciences, Inc. insiders filed 0 open-market purchases and 11 sales; 2,293 institutions reported holding it in 13F filings for Q2 2026, worth $140.5B in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in Gilead Sciences, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 1,722
- +56 vs. Q2 2024
- Shares held
- 1.04B
- +127.8M (+13.9%) vs. Q2 2024
- Total value
- $87.7B
- +$24.8B (+39.5%) vs. Q2 2024
- New holders
- 171
- 629 more added
- Sold out
- 115
- 698 more reduced
17 institutions that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting GILD on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 2,293 | $140.5B |
| Q1 2026 | 2,330 | $151.6B |
| Q4 2025 | 2,224 | $137.2B |
| Q3 2025 | 2,033 | $117.3B |
| Q2 2025 | 2,024 | $119.2B |
| Q1 2025 | 2,018 | $119.1B |
| Q4 2024 | 1,887 | $98.2B |
| Q3 2024 | 1,722 | $87.7B |
| Q2 2024 | 1,683 | $71.3B |
| Q1 2024 | 1,723 | $76.2B |
| Q4 2023 | 1,781 | $84.9B |
| Q3 2023 | 1,688 | $78.1B |
| Q2 2023 | 1,705 | $80.5B |
| Q1 2023 | 1,741 | $86.1B |
| Q4 2022 | 1,771 | $88.5B |
| Q3 2022 | 1,604 | $62.2B |
| Q2 2022 | 1,606 | $61.7B |
| Q1 2022 | 1,602 | $59.2B |
| Q4 2021 | 1,685 | $73.4B |
| Q3 2021 | 1,568 | $70.1B |
| Q2 2021 | 1,550 | $68.5B |
| Q1 2021 | 1,572 | $63.4B |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Gilead Sciences, Inc.; share changes are against Q2 2024.